NO2658525T3 - - Google Patents

Info

Publication number
NO2658525T3
NO2658525T3 NO11822867A NO11822867A NO2658525T3 NO 2658525 T3 NO2658525 T3 NO 2658525T3 NO 11822867 A NO11822867 A NO 11822867A NO 11822867 A NO11822867 A NO 11822867A NO 2658525 T3 NO2658525 T3 NO 2658525T3
Authority
NO
Norway
Application number
NO11822867A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45809329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2658525(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2658525T3 publication Critical patent/NO2658525T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A01N25/10—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dentistry (AREA)
  • Toxicology (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
NO11822867A 2010-12-29 2011-12-29 NO2658525T3 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061428007P 2010-12-29 2010-12-29

Publications (1)

Publication Number Publication Date
NO2658525T3 true NO2658525T3 (en:Method) 2018-01-27

Family

ID=45809329

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11822867A NO2658525T3 (en:Method) 2010-12-29 2011-12-29

Country Status (36)

Country Link
US (9) US9023897B2 (en:Method)
EP (3) EP3257498B1 (en:Method)
JP (2) JP6134269B2 (en:Method)
KR (1) KR101741055B1 (en:Method)
CN (1) CN103491946B (en:Method)
AU (1) AU2011350898B2 (en:Method)
BR (1) BR112013016662B1 (en:Method)
CA (1) CA2822854C (en:Method)
CL (1) CL2013001942A1 (en:Method)
CO (1) CO6751290A2 (en:Method)
CU (1) CU24203B1 (en:Method)
CY (1) CY1119829T1 (en:Method)
DK (1) DK2658525T3 (en:Method)
EA (1) EA027046B1 (en:Method)
ES (3) ES2647614T3 (en:Method)
FI (1) FI3586825T3 (en:Method)
HR (1) HRP20171810T1 (en:Method)
HU (1) HUE037349T2 (en:Method)
IL (1) IL227235A (en:Method)
LT (1) LT2658525T (en:Method)
MA (1) MA34832B1 (en:Method)
ME (1) ME02915B (en:Method)
MX (1) MX347090B (en:Method)
MY (1) MY165655A (en:Method)
NO (1) NO2658525T3 (en:Method)
NZ (1) NZ612326A (en:Method)
PL (3) PL3257498T3 (en:Method)
PT (1) PT2658525T (en:Method)
RS (1) RS56550B1 (en:Method)
SG (2) SG191414A1 (en:Method)
SI (1) SI2658525T1 (en:Method)
SM (1) SMT201700550T1 (en:Method)
TN (1) TN2013000267A1 (en:Method)
UA (1) UA112069C2 (en:Method)
WO (1) WO2012090070A2 (en:Method)
ZA (1) ZA201304687B (en:Method)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN11063A (en:Method) * 2012-06-27 2015-09-25 Medincell
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
EP2896402A1 (en) 2014-01-20 2015-07-22 Vect-Horus Activated neurotensin molecules and the uses thereof
CA2938019A1 (en) 2014-01-27 2015-07-30 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
FR3027522B1 (fr) * 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
JP6739455B2 (ja) * 2015-03-12 2020-08-12 クロス・バイオサイエンシズ・ベー・フェー 無水生体適合性複合材料
EP3352735B1 (en) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
CN108778245B (zh) * 2015-11-16 2022-05-13 美蒂森 一种用于使药物活性成分微粒化和/或靶向滑膜组织的方法
EP4378535A3 (en) 2016-11-16 2024-06-12 Persica Pharmaceuticals Ltd. Antibiotic formulations for lower back pain
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
FI3655038T3 (fi) * 2017-07-17 2025-02-11 Medincell S A Farmaseuttinen koostumus
KR20240146109A (ko) 2017-10-04 2024-10-07 패션 케미칼즈 게엠베하 운트 코. 카게 신규한 폴리락트산의 에스테르 및 이의 조성물
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
MX2022003051A (es) * 2019-09-13 2022-06-14 Medincell S A Formulaciones para la administracion de farmacos.
CN110638963A (zh) * 2019-11-01 2020-01-03 慧生医学科技(徐州)有限公司 一种可降解缓释药物组合物及制备方法
GB202010340D0 (en) 2020-07-06 2020-08-19 Medincell Pharmaceutical composition
CN116847827A (zh) 2020-12-16 2023-10-03 美蒂森股份公司 用于预防性治疗SARS-CoV-2病毒（COVID-19）的方法和组合物
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
KR20230158088A (ko) 2021-03-17 2023-11-17 메딘셀 에스.에이. 리스페리돈 및 생분해성 중합체를 포함하는 지속성의 주사용 제제
WO2022229402A1 (en) * 2021-04-30 2022-11-03 Medincell Sa New formulation
JP2024529009A (ja) 2021-07-06 2024-08-01 マーク・ヘースルトン セロトニン再取り込み阻害剤離脱症候群の治療
US20250009647A1 (en) 2021-08-05 2025-01-09 Medincell S.A. Pharmaceutical composition
WO2024052920A1 (en) * 2022-09-08 2024-03-14 Ramot At Tel-Aviv University Ltd. Programmable stimuli-responsive polymeric formulations
CN120569188A (zh) 2023-01-10 2025-08-29 美蒂森股份公司 奥氮平组合物和使用方法
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025224317A1 (en) * 2024-04-25 2025-10-30 Medincell S.A. A method for targeting pharmaceutically active principle in total knee replacement
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
DE68916860T2 (de) * 1988-05-23 1995-03-16 Procter & Gamble Aufsaugende Strukturen aus gemischten Zellstoffen.
US5632727A (en) 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5221534A (en) * 1989-04-26 1993-06-22 Pennzoil Products Company Health and beauty aid compositions
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
RU2178695C2 (ru) * 1993-11-19 2002-01-27 Жансен Фармасетика Н.В. Микрокапсулы, содержащие рисперидон, фармацевтическая композиция и способы их получения
KR0148704B1 (ko) 1994-01-10 1998-08-17 김상응 생체분해성 약물전달용 고분자
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
FR2741628B1 (fr) * 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
IL118235A0 (en) 1996-05-13 1996-09-12 Univ Ben Gurion Composition and method for forming biodegradable implants in situ and uses of these implants
US5711958A (en) * 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
EA008244B1 (ru) * 2002-05-03 2007-04-27 Янссен Фармацевтика Н.В. Полимерные микроэмульсии
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7160551B2 (en) 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
US7262253B2 (en) * 2003-12-02 2007-08-28 Labopharm, Inc. Process for the preparation of amphiphilic poly (N-vinyl-2-pyrrolidone) block copolymers
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
CA2609268A1 (en) * 2005-05-23 2006-11-30 University Of Utah Research Foundation Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
CN101309713A (zh) * 2005-11-17 2008-11-19 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
AR064286A1 (es) * 2006-12-13 2009-03-25 Quiceno Gomez Alexandra Lorena Produccion de dispositivos oftalmicos basados en la polimerizacion por crecimiento escalonado fotoinducida
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
JP2010215562A (ja) 2009-03-17 2010-09-30 Kansai Univ 膨隆剤組成物および膨隆剤製造方法

Also Published As

Publication number Publication date
RS56550B1 (sr) 2018-02-28
SG191414A1 (en) 2013-08-30
JP2017039758A (ja) 2017-02-23
SG10201508568VA (en) 2015-11-27
PL3257498T3 (pl) 2020-02-28
NZ612326A (en) 2014-10-31
FI3586825T3 (fi) 2023-03-20
US20190192665A1 (en) 2019-06-27
US20150157727A1 (en) 2015-06-11
JP2014502613A (ja) 2014-02-03
HRP20171810T1 (hr) 2017-12-29
WO2012090070A8 (en) 2013-08-08
LT2658525T (lt) 2017-12-11
KR20130135294A (ko) 2013-12-10
US20160030581A1 (en) 2016-02-04
CA2822854C (en) 2020-01-07
CU20130091A7 (es) 2013-08-29
US20190099495A1 (en) 2019-04-04
MX2013007682A (es) 2013-10-30
AU2011350898A1 (en) 2013-07-11
EP2658525A2 (en) 2013-11-06
PL3586825T3 (pl) 2023-04-11
ES2733915T3 (es) 2019-12-03
MX347090B (es) 2017-04-11
EP3257498A1 (en) 2017-12-20
ES2939744T3 (es) 2023-04-26
EA027046B1 (ru) 2017-06-30
PT2658525T (pt) 2017-11-30
EA201390783A1 (ru) 2013-12-30
US20210038724A1 (en) 2021-02-11
US20220202942A1 (en) 2022-06-30
ES2647614T3 (es) 2017-12-22
CN103491946A (zh) 2014-01-01
CL2013001942A1 (es) 2014-07-04
US9023897B2 (en) 2015-05-05
CY1119829T1 (el) 2018-06-27
EP3586825B1 (en) 2023-01-18
SMT201700550T1 (it) 2018-01-11
TN2013000267A1 (en) 2014-11-10
EP3586825A1 (en) 2020-01-01
PL2658525T3 (pl) 2018-02-28
WO2012090070A3 (en) 2012-11-01
BR112013016662A2 (pt) 2016-10-04
MY165655A (en) 2018-04-18
DK2658525T3 (da) 2017-11-13
UA112069C2 (uk) 2016-07-25
CA2822854A1 (en) 2012-07-05
US20210154301A1 (en) 2021-05-27
US20120172454A1 (en) 2012-07-05
KR101741055B1 (ko) 2017-05-29
SI2658525T1 (en) 2018-04-30
CO6751290A2 (es) 2013-09-16
CU24203B1 (es) 2016-09-30
US20230091533A1 (en) 2023-03-23
ZA201304687B (en) 2014-03-26
BR112013016662B1 (pt) 2021-08-03
CN103491946B (zh) 2016-08-10
EP2658525B1 (en) 2017-08-30
EP3257498B1 (en) 2019-04-24
MA34832B1 (fr) 2014-01-02
IL227235A (en) 2016-05-31
WO2012090070A2 (en) 2012-07-05
AU2011350898B2 (en) 2016-09-08
JP6134269B2 (ja) 2017-05-24
HUE037349T2 (hu) 2018-08-28
ME02915B (me) 2018-04-20
JP6302983B2 (ja) 2018-03-28

Similar Documents

Publication Publication Date Title
BR112013008959A2 (en:Method)
BR112012019354A2 (en:Method)
BR112012029986A2 (en:Method)
BR112012024897A2 (en:Method)
BR112012031500A2 (en:Method)
BR112012025307A2 (en:Method)
BR112012017960A2 (en:Method)
BR112012002126A2 (en:Method)
BR112013006400A2 (en:Method)
BR112012031826A2 (en:Method)
BR112012023249A2 (en:Method)
BR112012016456A2 (en:Method)
NO2658525T3 (en:Method)
BR112012018256A2 (en:Method)
BR112013010949A2 (en:Method)
BR112012023265A2 (en:Method)
BR112012024872A2 (en:Method)
BR112013003284A2 (en:Method)
BR112013002646A2 (en:Method)
BR112012022788A2 (en:Method)
BR112012016895A2 (en:Method)
BR112012023446A2 (en:Method)
BR112013006825A2 (en:Method)
BR112013007728A2 (en:Method)
BR112013007731A2 (en:Method)